Martínez E - Search Results

1

Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients.

Guardo AC, Zarama A, González T, Bargalló ME, Rojas J, Martínez E, Plana M, Sánchez-Palomino S. Guardo AC, et al. Among authors: martinez e. AIDS. 2019 May 1;33(6):965-972. doi: 10.1097/QAD.0000000000002169. AIDS. 2019. PMID: 30946150

2

Short communication: reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy.

Miró O, López S, Martínez E, Rodríguez-Santiago B, Blanco JL, Milinkovic A, Miró JM, Nunes V, Casademont J, Gatell JM, Cardellach F. Miró O, et al. Among authors: martinez e. AIDS Res Hum Retroviruses. 2003 Nov;19(11):1027-32. doi: 10.1089/088922203322588387. AIDS Res Hum Retroviruses. 2003. PMID: 14678610 Free article.

3

Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy.

Navarrete P, Morente V, García F, Alós L, Arnedo M, Plana M, Gil C, Caballero M, Miró JM, Martínez E, Fumero E, Castro P, Blanco JL, Mallolas J, Blanch JL, Cruceta A, Mestre G, Pumarola T, Gallart T, Gatell JM. Navarrete P, et al. Among authors: martinez e. Antivir Ther. 2003 Dec;8(6):635-7. Antivir Ther. 2003. PMID: 14760898

4

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.

Martínez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F, Larrousse M, León A, de Lazzari E, Gatell JM. Martínez E, et al. Clin Infect Dis. 2004 Apr 1;38(7):1017-23. doi: 10.1086/382531. Epub 2004 Mar 15. Clin Infect Dis. 2004. PMID: 15034836

5

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM. García F, et al. Among authors: martinez e. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13. doi: 10.1097/00126334-200406010-00007. J Acquir Immune Defic Syndr. 2004. PMID: 15167289

6

Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.

Martínez E, Milinkovic A, de Lazzari E, Ravasi G, Blanco JL, Larrousse M, Mallolas J, García F, Miró JM, Gatell JM. Martínez E, et al. Lancet. 2004 Jul 3-9;364(9428):65-7. doi: 10.1016/S0140-6736(04)16591-4. Lancet. 2004. PMID: 15234858

7

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, Bargallo X, García-Criado A, de Lazzari E, Larrousse M, León A, Loncá M, Milinkovic A, Gatell JM, Mallolas J. Laguno M, et al. Among authors: martinez e. AIDS. 2004 Sep 3;18(13):F27-36. doi: 10.1097/00002030-200409030-00003. AIDS. 2004. PMID: 15316335 Clinical Trial.

8

Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.

León A, Martinez E, Mallolas J, Laguno M, Blanco JL, Pumarola T, Gatell JM. León A, et al. Among authors: martinez e. AIDS. 2005 Jan 28;19(2):213-5. doi: 10.1097/00002030-200501280-00017. AIDS. 2005. PMID: 15668550

9

Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.

Blanco JL, Biglia MA, Arnedo M, Martínez E, Mallolas J, Milinkovic A, Laguno M, Larrousse M, Leon A, Lonca M, García F, Miró JM, Pumarola T, Gatell JM. Blanco JL, et al. Among authors: martinez e. AIDS. 2005 May 20;19(8):829-31. doi: 10.1097/01.aids.0000168978.89961.22. AIDS. 2005. PMID: 15867498

10

Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.

Ochoa de Echagüen A, Arnedo M, Xercavins M, Martinez E, Rosón B, Ribera E, Domingo P, González A, Riera M, Llibre JM, Gatell JM, Dalmau D; Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team. Ochoa de Echagüen A, et al. Among authors: martinez e. AIDS. 2005 Sep 2;19(13):1385-91. doi: 10.1097/01.aids.0000181010.85255.3c. AIDS. 2005. PMID: 16103769 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,628 results

Search Page